NICE gives final nod to Novartis, Forest CF drugs; Sinopharm aims for $515M stock offering;

@FiercePharma: Conquering the complexities of biologics to get to biosimilars. Special report | Follow @FiercePharma

@EricPFierce: Alexion files 8-K saying FDA is not impressed with its manufacturing at its Rhode Island plant. 8-K filing | Follow @EricPFierce

> U.K. cost-effectiveness watchdogs gave their final approval to cystic fibrosis drugs from Novartis ($NVS) and Forest Laboratories ($FRX). Report

> China's biggest drug distributor, Sinopharm, plans to raise up to $515 million by selling Hong Kong shares, aiming to expand its distribution and retail network. Report

> Pfizer ($PFE) settled a lawsuit with a Boulder, CO, couple who had sued over the death of their dog, Sophie, which was given the drug Rimadyl after surgery. Report

> Novartis will sell off part of its stake in an Indian subsidiary to meet Securities and Exchange Board requirements for minimum public shareholding in listed companies. Report

Medical Device News

 @FierceMedDev: CMO adds 200 medical device jobs in Ireland. Report | Follow @FierceMedDev

 @MarkHFierce: A new FMD feature--this week in FDA med tech violations, the device industry's police blotter. More | Follow @MarkHFierce

 @DamianFierce: Abbott won the FDA's OK for a diagnostic that detects birth defects and testicular cancer progress. News | Follow @DamianFierce

> U.K.'s Consort Medical mulls Dx expansion. Report

> Bacterin 2012 revenue climbs but losses also grow. Item

Biotech News

 @FierceBiotech: From FierceBiotechResearch.com: New drug could combat resistant #malaria strains. Story | Follow @FierceBiotech

@JohnCFierce: 3 yrs after its first CRL, A.P. Pharma gets another. Insists it can do a quick turnaround, but wrong again on FDA: News | Follow @JohnCFierce

@RyanMFierce: With big RNA deal, AstraZeneca's Soriot signals yen for risky science. More | Follow @RyanMFierce

> Connecticut pols stunned as Pfizer brings in the wrecking ball. Item

> Repros shares boom on promising PhIII results for testosterone drug. Report

> Biogen Idec rolls up FDA OK for blockbuster multiple sclerosis drug Tecfidera. News

Vaccines News

> GSK vaccine plant helps U.S. arm for biodefense. Report

> Taboo topics: Sex, politics, religion... and vaccines? Article

> Swedish study adds to data linking GSK vax to narcolepsy. Item

> FDA moves decision day for GSK pandemic vaccine, but why? More

Pharma Manufacturing News

> Alexion gets warning letter for Soliris plant. Report

> FDA lifts ban on some Aurobindo antibiotics. News

> Injection point: BD, Teva, Hikma target sterile injectables. Story

> GSK gets OK for $91M vaccine plant with Texas A&M. Article

And Finally... Is modern life too cozy for our inborn survival instincts? Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.